Lecture: CTSA Visiting Scholars: Therapeutic Advances in Hereditary Hemorrhagic Telangiectasia

Hereditary hemorrhagic telangiectasia (HHT) is a hereditary multisystem vascular disease of abnormal angiogenesis and the second most common hereditary bleeding disorder in the world.

Harvard KL2 Scholar Hanny Al-Samkari, MD will describe the revolutionary potential of anti-angiogenic therapy in HHT and the evidence to date for systemic bevacizumab as a treatment for bleeding and anemia in HHT.

Date
- Add to Calendar 2021-04-08 12:00:00 2021-04-08 13:00:00 Lecture: CTSA Visiting Scholars: Therapeutic Advances in Hereditary Hemorrhagic Telangiectasia https://apps.research.unc.edu/events/index.cfm?event=events.eventDetails&event_key=E1C3BF592E5F948E6002E17D0862BC02150B77A4

Hereditary hemorrhagic telangiectasia (HHT) is a hereditary multisystem vascular disease of abnormal angiogenesis and the second most common hereditary bleeding disorder in the world.

Harvard KL2 Scholar Hanny Al-Samkari, MD will describe the revolutionary potential of anti-angiogenic therapy in HHT and the evidence to date for systemic bevacizumab as a treatment for bleeding and anemia in HHT.

https://clic-ctsa.org/events/lecture-ctsa-visiting-scholars-therapeutic-advances-hereditary-hemorrhagic-telangiectasia University Of North Carolina Chapel Hill admin@clic-ctsa.org America/New_York public
Activity Type
Webinar
Location Type
Online
https://apps.research.unc.edu/events/index.cfm?event=events.eventDetails&event_…